TRCT
PNT

Tower Research Capital (TRC)’s POINT Biopharma Global Inc. Common Stock PNT Stock Holding History

Tower Research Capital (TRC)’s Portfolio PNT Stock Details PNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-2,624
Closed -$17.5K – 6275
2023
Q3 		$17.5K Sell
2,624
-4,319
-62% -$35.9K ﹤0.01% 3499
2023
Q2 		$62.9K Buy
6,943
+3,862
+125% +$34.1K ﹤0.01% 2393
2023
Q1 		$22K Buy
3,081
+1,340
+77% +$9.94K ﹤0.01% 3362
2022
Q4 		$13K Sell
1,741
-9,142
-84% -$67.8K ﹤0.01% 3657
2022
Q3 		$84K Sell
10,883
-660
-6% -$5.6K ﹤0.01% 2717
2022
Q2 		$79K Buy
+11,543
New +$88.3K ﹤0.01% 2479
2022
Q1 		– Sell
-8,164
Closed -$46K – 6779
2021
Q4 		$46K Buy
8,164
+4,303
+111% +$32.3K ﹤0.01% 2829
2021
Q3 		$30K Buy
+3,861
New +$35.2K ﹤0.01% 3383
2021
Q2 		– Sell
-220
Closed -$2K – 5985
2021
Q1 		$2K Buy
+220
New +$2.98K ﹤0.01% 5073

Other funds holding PNT

BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return

Tower Research Capital (TRC)'s PNT Position: Q4 2023 in Review

Tower Research Capital (TRC) sold out of POINT Biopharma Global Inc. Common Stock (PNT) in Q4 2023, closing a stake of 2,624 shares — an estimated $17.5K sold.

Tower Research Capital (TRC) first reported a position in PNT in Q1 2021 and held it in 9 quarters. The position peaked at $84K in Q3 2022. 1 fund tracked by Wall St. Rank holds PNT as of Q4 2023.

  • Tower Research Capital (TRC) reported no remaining POINT Biopharma Global Inc. Common Stock position as of Q4 2023 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,624 POINT Biopharma Global Inc. Common Stock shares in Q4 2023, an estimated $17.5K.
  • Tower Research Capital (TRC) first reported a position in POINT Biopharma Global Inc. Common Stock in Q1 2021 and held it in 9 quarters.
  • Tower Research Capital (TRC)'s POINT Biopharma Global Inc. Common Stock position peaked at $84K in Q3 2022.
  • 1 fund tracked by Wall St. Rank held POINT Biopharma Global Inc. Common Stock as of Q4 2023.

Based on Tower Research Capital (TRC)'s 13F filing for Q4 2023, filed 13 Feb 2024.